Explore
Validate
LearnHPA011741
antibody from Atlas Antibodies
Targeting: NPRL3
C16orf35, CGTHBA, HS-40, MARE, NPR3, RMD11
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA011741 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA011741, RRID:AB_1845577
- Product name
- Anti-NPRL3
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human NPRL3, Gene description: nitrogen permease regulator-like 3 (S. cerevisiae), Alternative Gene Names: C16orf35, CGTHBA, HS-40, MARE, NPR3, RMD11, Validated applications: IHC, ICC, Uniprot ID: Q12980, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.1 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Redundant electrostatic interactions between GATOR1 and the Rag GTPase heterodimer drive efficient amino acid sensing in human cells
KAT7-mediated CANX (calnexin) crotonylation regulates leucine-stimulated MTORC1 activity
Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors
Doxsey D, Tettoni S, Egri S, Shen K
Journal of Biological Chemistry 2023;299(7):104880
Journal of Biological Chemistry 2023;299(7):104880
KAT7-mediated CANX (calnexin) crotonylation regulates leucine-stimulated MTORC1 activity
Yan G, Li X, Zheng Z, Gao W, Chen C, Wang X, Cheng Z, Yu J, Zou G, Farooq M, Zhu X, Zhu W, Zhong Q, Yan X
Autophagy 2022;18(12):2799-2816
Autophagy 2022;18(12):2799-2816
Huntington’s disease phenotypes are improved via mTORC1 modulation by small molecule therapy
Li Y, St-Cyr S, Child D, Giaime E, Smith A, Pascua C, Hahm S, Saiah E, Davidson B
PLOS ONE 2022;17(8):e0273710
PLOS ONE 2022;17(8):e0273710
Genomic Alterations in PIK3CA-Mutated Breast Cancer Result in mTORC1 Activation and Limit the Sensitivity to PI3Kα Inhibitors
Cai Y, Xu G, Wu F, Michelini F, Chan C, Qu X, Selenica P, Ladewig E, Castel P, Cheng Y, Zhao A, Jhaveri K, Toska E, Jimenez M, Jacquet A, Tran-Dien A, Andre F, Chandarlapaty S, Reis-Filho J, Razavi P, Scaltriti M
Cancer Research 2021;81(9):2470-2480
Cancer Research 2021;81(9):2470-2480
No comments: Submit comment
No validations: Submit validation data